Transcriptomics Market Outlook:
Transcriptomics Market size was estimated at over USD 9.2 billion in 2024 and is projected to reach USD 41.7 billion by the end of 2037, exhibiting a CAGR of 12.5% during the forecast period 2025-2037. In 2025, the industry size of the transcriptomics is evaluated at USD 10.5 billion.
The global transcriptomics market is expanding globally with a sustained engagement across research and clinical settings, with the rise in patient pool benefiting from transcriptomic and genomic profiling, especially for personalized precision medicine strategies. For example, the U.S. National Cancer Institute states that over 2.3 million new cancer cases were diagnosed in 2023. Meanwhile, transcriptomic technologies adoption is increasing rapidly and is utilized in tumor classification and treatment monitoring. Further, with respect to neurodegenerative and rare diseases, NIH NIH-related report depicts a continuous rise in patient cohorts recruited for transcriptome-based biomarker discovery, mainly under programs like the Accelerating Medicines Partnership (AMP) and the Rare Diseases Clinical Research Network.
On the basis of the supply chain, the trade and sourcing of raw materials and assembly for transcriptomics products heavily rely on globalized routes. According to the U.S. Census Bureau’s trade data, a nearly 14.9% rise has been seen in imports of biotechnological reagents and nucleic acid kits in 2023. This rise is particularly seen in manufacturers such as China, Germany, and South Korea. Meanwhile, the U.S. Bureau of Labor Statistics Producer Price Index (PPI) for biological product manufacturing climbed by 4.8% in 2023, while the Consumer Price Index (CPI) for medical care commodities rose by 4.0%, indicating upstream cost transfers to downstream clinical service providers. R&D funding continues to be substantial, with the NIH alone spending more than USD 750.9 million in 2023 for transcriptomics-related research in cancer, immunology, and brain diseases.
